With our AI platform, we provide CROs and biopharma with AI-powered solutions to identify novel pathology-based biomarkers that can accelerate drug development.
Aiosyn’s algorithms can be used to accelerate the development of biomarker-based therapeutic and patient stratification strategies
Our technology harnesses a powerful form of machine learning called “neural networks” (or deep learning) to identify abnormal tissue patterns such as cancer. Artificial intelligence has shown to do this with unprecedented accuracy and speed. For quantifying patterns and cells of interest, AI offers consistent quality, repeatability, and speed.